Tag Archives: Strategy

Alliance Management is Being Neglected, Says Study

Survey finds disconnect between perceived importance of alliance management function at  C-level and actual commitment to it. The Rhythm of Business has released the results of a recent study titled The Practice of Alliance Management in the Biopharmaceutical Industry that examines the state of alliance management in pharmaceutical companies. The study, co-sponsored by the Biopharma […]
Posted in Biotech, leadership, Strategy | Also tagged , | Leave a comment

Recasting Big Pharmas R&D Role: Wellcome Trust or Wal-Mart?

New research suggests it’s time industry took a radically different approach to drug development, leaving compound innovation to others while mobilizing its global scale and promotional muscle to drive timely acceptance in the marketplace. The biggest strategic issue confronting Big Pharma today is balancing that legacy of ”big” — maintaining the capacity to invest in […]
Posted in R&D, Strategy | Also tagged , | Leave a comment

MedImmune Bets Its Fate on “Biobetters”

AstraZeneca’s biologics shop makes a decisive move in the biosimilars market. MedImmune, the biologics shop bought by AstraZeneca (AZ) for a staggering $15 billion in 2007 promising one new drug a year for the foundering British firm, has made precious little news since the deal. But all of a sudden the post-Labor Day wires were […]
Posted in Biotech, Deals, Global, R&D, Strategy | Also tagged , , , , , | 1 Comment

How Do We Raise R&D Productivity?

That’s the big question that no one has answered yet. So perhaps its worth breaking it down into smaller parts, suggests Dr Brian D Smith. An ill-posed question is a mathematician’s term that well describes what many Big Pharma companies are asking themselves, namely, how can we raise R&D productivity? It’s ill-posed because it has […]
Posted in Europe, Global, Guest Blog, Marketing, Strategy | Also tagged , , | Leave a comment

Updated IMS Forecast Predicts Market Growth

If you look closely at the thunderclouds hovering over pharma, there is a ray of light peeking through the gloom—IMS’ updated 2009-2014 forecast has come in, and it’s a far cry from the unmitigated doom of recent years. Market growth in 2009 was 7 percent, a vast improvement over 2008’s 4.8 percent, and IMS expects […]
Posted in Strategy | Also tagged , , | Leave a comment
  • Categories

  • Meta